<DOC>
	<DOCNO>NCT00511940</DOCNO>
	<brief_summary>The purpose research study determine efficacy ( well work ) , tolerability safety acomprosate compare placebo patient binge eat disorder .</brief_summary>
	<brief_title>Acamprosate Treatment Binge-Eating Disorder</brief_title>
	<detailed_description />
	<mesh_term>Feeding Eating Disorders</mesh_term>
	<mesh_term>Binge-Eating Disorder</mesh_term>
	<mesh_term>Bulimia</mesh_term>
	<mesh_term>Acamprosate</mesh_term>
	<criteria>Subjects meet DSMIV ( 1 ) criterion diagnosis binge eat disorder ( BED ) least last 6 month . The DSMIV criterion follow : Recurrent episodes binge eat . An episode binge eat characterize following : eating , discrete period time ( eg , within two hour period ) , amount food definitely large people would eat similar period time similar condition ; sense lack control eat episode ( eg , feel one stop eat control much one eating ) . The binge eat episode associate least three follow : eat much rapidly normal ; eat uncomfortably full ; eat large amount food feeling physically hungry ; eat alone embarrass much one eating ; feel disgust oneself , depress , feel guilty overeating . Marked distress regard binge eating . The binge eating occur , average , least two day week six month . The episodes binge eat occur exclusively course bulimia nervosa anorexia nervosa . In addition , subject report least 3 binge eat episode per week last 6 month prior randomization Weight &gt; 85 % midpoint ideal body weight height . ( According Metropolitan Height/Weight table . ) The subject population expect include normal weight obese individual ( although majority subject expect overweight ) . Men woman , age 18 65 . The subject population expect predominantly make woman . Have concurrent symptom bulimia nervosa anorexia nervosa , include weight loss least 15 % Metropolitan Height/Weight table . Women pregnant , lactating , childbearing potential use adequate contraceptive measure . ( All woman childbearing potential negative pregnancy test enter study ) . Patients display clinically significant suicidality homicidality . Patients receive psychotherapy behavioral therapy mental health professional part previous treatment BED least 3 month prior randomization . A DSMIV diagnosis substance abuse dependence ( except nicotine abuse dependence ) within 6 month prior randomization . A lifetime DSMIV history psychosis , mania hypomania , dementia . History psychiatric personality disorder ( eg , schizotypal borderline ) might interfere diagnostic assessment , treatment , compliance . Clinically unstable medical disease , include cardiovascular , hepatic , renal , gastrointestinal , pulmonary , metabolic , endocrine systemic disease could interfere diagnosis , treatment , assessment BED . Patients biochemically euthyroid enter study . History seizure , include febrile seizure childhood . Patients require treatment drug might interact adversely obscure action study medication . Clinically relevant abnormal laboratory result , specifically include hypokalemia . Patients receive monoamine oxidase inhibitor , antipsychotic , lithium , fluoxetine within four week prior randomization . Patients receive psychoactive medication ( hypnotic ) within one week prior randomization . Patients receive investigational medication depot neuroleptic within three month prior randomization . Patients previously enrol study previously treat acamprosate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>